Well Referenced

Tag: glycemic control

Treatment of Diabetic Impotence with Umbilical Cord Blood Stem Cell Intracavernosal Transplant: Preliminary Report of 7 Cases

This 2010 pilot study assessed the safety and efficacy of intracavernosal injections of human umbilical cord blood stem cells (hUCBSCs) in seven male patients (ages 57–87) with type 2 diabetes mellitus and refractory erectile dysfunction (ED). Each patient received a single injection of 1.5×10⁷ hUCBSCs without immunosuppression. Over a 9-month

Read More »
June 26, 2025 No Comments

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

This 12-week, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in 383 Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise. Participants were randomized to receive placebo or canagliflozin at doses of 50, 100, 200, or

Read More »
June 26, 2025 No Comments

Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis

This 2012 systematic review and meta-analysis assessed the efficacy and safety of berberine in managing type 2 diabetes mellitus (T2DM). Analyzing 14 randomized controlled trials involving 1,068 participants, the study found that berberine significantly improved glycemic control and lipid profiles compared to lifestyle modifications or placebo. When compared to standard

Read More »
June 26, 2025 No Comments

Management of Diabetes Across the Course of Disease: Minimizing Obesity-Associated Complications

This comprehensive review addresses the intertwined relationship between obesity and type 2 diabetes mellitus (T2DM), emphasizing the importance of weight management throughout the disease course. It highlights that obesity not only increases the risk of developing T2DM but also exacerbates its complications. The article discusses various interventions, including lifestyle modifications

Read More »
June 26, 2025 No Comments

A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-On to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes

This 52-week, multinational, randomized, open-label, non-inferiority trial compared the efficacy and safety of insulin detemir and insulin glargine as add-on therapy to oral glucose-lowering drugs in insulin-naive adults with type 2 diabetes. A total of 582 participants were randomized to receive either insulin detemir or insulin glargine once daily, titrated

Read More »
June 26, 2025 No Comments

A New Treatment Strategy that Reduces Growth/Differentiation Factor-15 in Type-2 Diabetes Mellitus: Major Autohemotherapy: A Pilot Study

This pilot study evaluated the effects of major autohemotherapy with ozone infusion on reducing growth/differentiation factor-15 (GDF-15) and LDL cholesterol in patients with type-2 diabetes mellitus (T2DM). The treatment, administered twice weekly for 10 sessions, resulted in a significant reduction in GDF-15 and LDL cholesterol levels in the T2DM group,

Read More »
June 26, 2025 No Comments

Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial

This randomized controlled trial compared the effects of Myo-Inositol and Metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome (PCOS). The study found that both treatments improved insulin sensitivity and lipid metabolism, but Myo-Inositol showed superior results, particularly

Read More »
June 26, 2025 No Comments

Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review

This narrative review discusses the hepatoprotective benefits of silymarin, an extract from milk thistle, in treating liver diseases such as cirrhosis, non-alcoholic fatty liver disease, and drug-induced liver injury. Clinical studies demonstrated that silymarin reduces oxidative stress, improves liver function, and offers potential benefits in glycemic control for patients with

Read More »
June 26, 2025 No Comments

Efficacy and Safety of Oral Magnesium Supplementation in the Treatment of Depression in the Elderly With Type 2 Diabetes: A Randomized, Equivalent Trial

This 2008 randomized controlled trial evaluated the effectiveness of oral magnesium supplementation versus imipramine in treating depression among elderly patients with type 2 diabetes. The study found that magnesium was equally effective as imipramine in improving depression scores, while offering a more favorable side effect profile. Magnesium’s role in neurotransmitter

Read More »
June 26, 2025 No Comments

The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes

This observational study evaluated the lipid-modulating effects of exenatide in 35 newly diagnosed type 2 diabetes mellitus (T2DM) patients over 12 weeks. Using a lipidomic approach, researchers identified that exenatide significantly reduced several lipid species—sphingomyelins, lysophosphatidylcholines (LPC 16:0), and lysophosphatidylethanolamines (LPE 18:0)—previously elevated in T2DM patients compared to healthy controls.

Read More »
June 26, 2025 No Comments